Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo therapy aims to control advanced breast cancer

NCT ID NCT05900895

Recruiting now Disease control Sponsor: Mary D Chamberlin Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests the safety of combining two drugs, olaparib and estradiol, in post-menopausal women with advanced ER+/HER2- breast cancer that has spread or returned. The goal is to find the best dose for future studies. About 6 participants will be enrolled.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ER+/HER2- BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm estrogen-receptor positive breast cancer Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC BREAST CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Dartmouth Cancer Center

    RECRUITING

    Lebanon, New Hampshire, 03756, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.